(Circulation. 1996;94:273-278.)
© 1996 American Heart Association, Inc.
Articles |
Apolipoprotein A-I and B Levels and the Risk of Ischemic Heart Disease During a Five-Year Follow-up of Men in the Quebec Cardiovascular Study
the Lipid Research Center, Laval University Hospital Research Center, Ste-Foy (B.L., S.M., P.J.L., B.C., J.-P.D.); the Department of Social and Preventive Medicine, Laval University, Quebec (P.-M.B.); and the Department of Medicine, University of Montreal (G.R.D.), Quebec, Canada.
Correspondence to Dr Jean-Pierre Despres, PhD, Professor and Director, Lipid Research Center, CHUL Research Center, 2705 Laurier Blvd, Ste-Foy, Quebec, Canada G1V 4G2. E-mail jpierre.despres@crchul.ulaval.ca.
Background Results obtained largely from case-control studies have suggested that an elevated plasma concentration of apolipoprotein (apo) B may be considered an important risk factor for ischemic heart disease (IHD). Prospective data on the relevance of measuring apo A-I and apo B levels in the assessment of IHD risk, however, remain sparse as well as controversial.
Methods and Results Plasma lipid, apo B, and apo A-I levels as well as other risk factors were evaluated at baseline in 1985 in a sample of 2155 men (45 to 76 years old) who were followed for a period of 5 years for clinical signs of IHD. Proportional-hazards analyses indicated that plasma apo B concentrations measured at entry were strongly associated with onset of IHD (relative rate, 1.4; 95% confidence interval [CI], 1.2 to 1.7), independent of covariables such as age, smoking, diabetes mellitus, and systolic blood pressure. Controlling for triglycerides, HDL cholesterol, and total/HDL cholesterol ratio did not eliminate the relationship between plasma apo B levels and IHD. The association between apo A-I and IHD was of lower magnitude (relative rate, 0.85; 95% CI, 0.7 to 1.0), and adjustment for selected plasma lipid and lipoprotein levels eliminated this association. Stepwise logistic regression analysis revealed that, among metabolic variables, apo B was the strongest correlate of IHD.
Conclusions These prospective results emphasize the importance of apo B as a risk factor for IHD. Apo B may be regarded as a relevant tool in the assessment of IHD risk in men, because it may provide information that would not be obtained from the conventional lipid-lipoprotein profile.
Key Words: apolipoproteins • ischemia • heart diseases • lipoproteins
This article has been cited by other articles:
 |
|
 |
|
  L. Johansson and C. Schmidt Increased apoB/apoA-I Ratio Is Predictive of Peripheral Arterial Disease in Initially Healthy 58-Year-old Men During 8.9 Years of Follow-up Angiology, October 1, 2009; 60(5): 539 - 545. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Tu, S. Bhasin, P. W. Hruz, K. L. Herbst, L. W. Castellani, N. Hua, J. A. Hamilton, and W. Guo Genetic Disruption of Myostatin Reduces the Development of Proatherogenic Dyslipidemia and Atherogenic Lesions In Ldlr Null Mice Diabetes, August 1, 2009; 58(8): 1739 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Superko Advanced Lipoprotein Testing and Subfractionation Are Clinically Useful Circulation, May 5, 2009; 119(17): 2383 - 2395. [Full Text] [PDF]
|
|
|
|
 |
|
 V. W. Tsai, J. Cooper, H. Garan, A. Natale, L. M. Ptaszek, P. T. Ellinor, K. Hickey, R. Downey, P. Zei, H. Hsia, et al. The Efficacy of Implantable Cardioverter-Defibrillators in Heart Transplant Recipients: Results From a Multicenter Registry Circ Heart Fail, May 1, 2009; 2(3): 197 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Nuzum and T. Merz Macrovascular Complications of Diabetes Mellitus Journal of Pharmacy Practice, April 1, 2009; 22(2): 135 - 148. [Abstract] [PDF]
|
|
|
|
 |
|
 J. H. Contois, J. P. McConnell, A. A. Sethi, G. Csako, S. Devaraj, D. M. Hoefner, and G. R. Warnick Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clin. Chem., March 1, 2009; 55(3): 407 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Ballantyne, J. S. Raichlen, and V. A. Cain Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Targets in High-Risk Patients: The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) Trial J. Am. Coll. Cardiol., August 19, 2008; 52(8): 626 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Juonala, J. S.A. Viikari, M. Kahonen, T. Solakivi, H. Helenius, A. Jula, J. Marniemi, L. Taittonen, T. Laitinen, T. Nikkari, et al. Childhood Levels of Serum Apolipoproteins B and A-I Predict Carotid Intima-Media Thickness and Brachial Endothelial Function in Adulthood: The Cardiovascular Risk in Young Finns Study J. Am. Coll. Cardiol., July 22, 2008; 52(4): 293 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gozal, O. S. Capdevila, and L. Kheirandish-Gozal Metabolic Alterations and Systemic Inflammation in Obstructive Sleep Apnea among Nonobese and Obese Prepubertal Children Am. J. Respir. Crit. Care Med., May 15, 2008; 177(10): 1142 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Frontini, S. R. Srinivasan, J. Xu, R. Tang, M. G. Bond, and G. S. Berenson Usefulness of Childhood Non-High Density Lipoprotein Cholesterol Levels Versus Other Lipoprotein Measures in Predicting Adult Subclinical Atherosclerosis: The Bogalusa Heart Study Pediatrics, May 1, 2008; 121(5): 924 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1512 - 1524. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care, April 1, 2008; 31(4): 811 - 822. [Full Text] [PDF]
|
|
|
|
 |
|
 K.-L. Chien, H.-C. Hsu, T.-C. Su, M.-F. Chen, Y.-T. Lee, and F. B. Hu Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese J. Lipid Res., November 1, 2007; 48(11): 2499 - 2505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ingelsson, E. J. Schaefer, J. H. Contois, J. R. McNamara, L. Sullivan, M. J. Keyes, M. J. Pencina, C. Schoonmaker, P. W. F. Wilson, R. B. D'Agostino, et al. Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women JAMA, August 15, 2007; 298(7): 776 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lanas, A. Avezum, L. E. Bautista, R. Diaz, M. Luna, S. Islam, S. Yusuf, and for the INTERHEART Investigators in Latin America Risk Factors for Acute Myocardial Infarction in Latin America: The INTERHEART Latin American Study Circulation, March 6, 2007; 115(9): 1067 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, J. E. Buring, N. Rifai, and N. R. Cook Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women: The Reynolds Risk Score JAMA, February 14, 2007; 297(6): 611 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Joshi, S. Islam, P. Pais, S. Reddy, P. Dorairaj, K. Kazmi, M. R. Pandey, S. Haque, S. Mendis, S. Rangarajan, et al. Risk Factors for Early Myocardial Infarction in South Asians Compared With Individuals in Other Countries JAMA, January 17, 2007; 297(3): 286 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zarich, C. Luciano, J. Hulford, and A. Abdullah Prevalence of metabolic syndrome in young patients with acute MI: does the Framingham Risk Score underestimate cardiovascular risk in this population? Diabetes and Vascular Disease Research, September 1, 2006; 3(2): 103 - 107. [Abstract] [PDF]
|
|
|
|
|
|
S. R. Srinivasan, M. G. Frontini, J. Xu, and G. S. Berenson Utility of Childhood Non-High-Density Lipoprotein Cholesterol Levels in Predicting Adult Dyslipidemia and Other Cardiovascular Risks: The Bogalusa Heart Study Pediatrics, July 1, 2006; 118(1): 201 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]
|
|
|
|
|
|
P. Berhanu, M. S Kipnes, M. A Khan, A. T Perez, S. F Kupfer, R. G Spanheimer, S. Demissie, and P. R Fleck Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy Diabetes and Vascular Disease Research, May 1, 2006; 3(1): 39 - 44. [Abstract] [PDF]
|
|
|
|
 |
|
 D.C. Chan and G.F. Watts Apolipoproteins as markers and managers of coronary risk QJM, May 1, 2006; 99(5): 277 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ingelsson, J. Arnlov, J. Sundstrom, B. Zethelius, B. Vessby, and L. Lind Novel Metabolic Risk Factors for Heart Failure J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2054 - 2060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Denke Weighing in Before the Fight: Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Versus Apolipoprotein B as the Best Predictor for Coronary Heart Disease and the Best Measure of Therapy Circulation, November 29, 2005; 112(22): 3368 - 3370. [Full Text] [PDF]
|
|
|
|
|
|
T. Pischon, C. J. Girman, F. M. Sacks, N. Rifai, M. J. Stampfer, and E. B. Rimm Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men Circulation, November 29, 2005; 112(22): 3375 - 3383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, N. Rifai, N. R. Cook, G. Bradwin, and J. E. Buring Non-HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women JAMA, July 20, 2005; 294(3): 326 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Meisinger, H. Loewel, W. Mraz, and W. Koenig Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study Eur. Heart J., February 1, 2005; 26(3): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Bosse, Y. C. Chagnon, J.-P. Despres, T. Rice, D. C. Rao, C. Bouchard, L. Perusse, and M.-C. Vohl Compendium of genome-wide scans of lipid-related phenotypes: adding a new genome-wide search of apolipoprotein levels J. Lipid Res., December 1, 2004; 45(12): 2174 - 2184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Shai, E. B. Rimm, S. E. Hankinson, G. Curhan, J. E. Manson, N. Rifai, M. J. Stampfer, and J. Ma Multivariate Assessment of Lipid Parameters as Predictors of Coronary Heart Disease Among Postmenopausal Women: Potential Implications for Clinical Guidelines Circulation, November 2, 2004; 110(18): 2824 - 2830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Carmena, P. Duriez, and J.-C. Fruchart Atherogenic Lipoprotein Particles in Atherosclerosis Circulation, June 15, 2004; 109(23_suppl_1): III-2 - III-7. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. C. Carr and J. D. Brunzell Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2601 - 2607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lamarche and S. Desroches Metabolic syndrome and effects of conjugated linoleic acid in obesity and lipoprotein disorders: the Quebec experience Am. J. Clinical Nutrition, June 1, 2004; 79(6): 1149S - 1152S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Perez, M. Khan, T. Johnson, and M. Karunaratne Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes Diabetes and Vascular Disease Research, May 1, 2004; 1(1): 44 - 50. [Abstract] [PDF]
|
|
|
|
|
|
M. Averina, O. Nilssen, T. Brenn, J. Brox, V. L. Arkhipovsky, and A. G. Kalinin Factors behind the Increase in Cardiovascular Mortality in Russia: Apolipoprotein AI and B Distribution in the Arkhangelsk Study 2000 Clin. Chem., February 1, 2004; 50(2): 346 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-f. Cheung, T.-c. Yung, S. C. F. Tam, M. H. K. Ho, and A. K. T. Chau Novel and traditional cardiovascular risk factors in children after Kawasaki disease: Implications for premature atherosclerosis J. Am. Coll. Cardiol., January 7, 2004; 43(1): 120 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Moore, M.-a. Kawashiri, K. Kitajima, A. Secreto, J. S. Millar, D. Pratico, and D. J. Rader Apolipoprotein A-I Deficiency Results in Markedly Increased Atherosclerosis in Mice Lacking the LDL Receptor Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1914 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Wagner, O. Jorba, R. Bonet, J. Ordonez-Llanos, and A. Perez Efficacy of Atorvastatin and Gemfibrozil, Alone and in Low Dose Combination, in the Treatment of Diabetic Dyslipidemia J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3212 - 3217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.J. Packard Apolipoproteins: the new prognostic indicator? Eur. Heart J. Suppl., June 1, 2003; 5(suppl_D): D9 - D16. [Abstract] [PDF]
|
|
|
|
|
|
M. Faraj, P. J. Havel, S. Phelis, D. Blank, A. D. Sniderman, and K. Cianflone Plasma Acylation-Stimulating Protein, Adiponectin, Leptin, and Ghrelin before and after Weight Loss Induced by Gastric Bypass Surgery in Morbidly Obese Subjects J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1594 - 1602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Gibbons, J. Abrams, K. Chatterjee, J. Daley, P. C. Deedwania, J. S. Douglas, T. B. Ferguson Jr, S. D. Fihn, T. D. Fraker Jr, J. M. Gardin, et al. ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina) Circulation, January 7, 2003; 107(1): 149 - 158. [Full Text] [PDF]
|
|
|
|
|
|
Committee Members, R. J. Gibbons, J. Abrams, K. Chatterjee, J. Daley, P. C. Deedwania, J. S. Douglas, T. B. Ferguson Jr, S. D. Fihn, T. D. Fraker Jr, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina) J. Am. Coll. Cardiol., January 1, 2003; 41(1): 159 - 168. [Full Text] [PDF]
|
|
|
|
|
|
References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]
|
|
|
|
|
|
P. J. Talmud, E. Hawe, G. J. Miller, and S. E. Humphries Nonfasting Apolipoprotein B and Triglyceride Levels as a Useful Predictor of Coronary Heart Disease Risk in Middle-Aged UK Men Arterioscler Thromb Vasc Biol, November 1, 2002; 22(11): 1918 - 1923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Blake, J. D. Otvos, N. Rifai, and P. M Ridker Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women Circulation, October 8, 2002; 106(15): 1930 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Srinivasan, L. Myers, and G. S. Berenson Distribution and Correlates of Non-High-Density Lipoprotein Cholesterol in Children: The Bogalusa Heart Study Pediatrics, September 1, 2002; 110(3): e29 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M Davy, K. P Davy, R. C Ho, S. D Beske, L. R Davrath, and C. L Melby High-fiber oat cereal compared with wheat cereal consumption favorably alters LDL-cholesterol subclass and particle numbers in middle-aged and older men Am. J. Clinical Nutrition, August 1, 2002; 76(2): 351 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Luc, J.-M. Bard, J. Ferrieres, A. Evans, P. Amouyel, D. Arveiler, J.-C. Fruchart, P. Ducimetiere, and on behalf of the PRIME Study Group Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1155 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Miremadi, A. Sniderman, and J. Frohlich Can Measurement of Serum Apolipoprotein B Replace the Lipid Profile Monitoring of Patients with Lipoprotein Disorders? Clin. Chem., March 1, 2002; 48(3): 484 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E Roeters van Lennep, H.T. Westerveld, D.W. Erkelens, and E. E van der Wall Risk factors for coronary heart disease: implications of gender Cardiovasc Res, February 15, 2002; 53(3): 538 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Aguilar-Salinas, A. Delgado, F. J. Gomez-Perez, Y. Cui, R. S. Blumenthal, M. K. Whiteman, and J. A. Flaws The Advantages of Using Non-HDL-C in the Diagnosis and Treatment of Dyslipidemia Arch Intern Med, January 14, 2002; 162(1): 108 - 109. [Full Text] [PDF]
|
|
|
|
|
|
I. Lemieux, B. Lamarche, C. Couillard, A. Pascot, B. Cantin, J. Bergeron, G. R. Dagenais, and J.-P. Despres Total Cholesterol/HDL Cholesterol Ratio vs LDL Cholesterol/HDL Cholesterol Ratio as Indices of Ischemic Heart Disease Risk in Men: The Quebec Cardiovascular Study Arch Intern Med, December 10, 2001; 161(22): 2685 - 2692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Sniderman, T. Scantlebury, and K. Cianflone Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus Ann Intern Med, September 18, 2001; 135(6): 447 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Sharrett, C. M. Ballantyne, S. A. Coady, G. Heiss, P. D. Sorlie, D. Catellier, and W. Patsch Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study Circulation, September 4, 2001; 104(10): 1108 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hermansen, M. Søndergaard, L. Høie, M. Carstensen, and B. Brock Beneficial Effects of a Soy-Based Dietary Supplement on Lipid Levels and Cardiovascular Risk Markers in Type 2 Diabetic Subjects Diabetes Care, February 1, 2001; 24(2): 228 - 233. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. D. Sniderman, J. Bergeron, and J. Frohlich Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial Can. Med. Assoc. J., January 1, 2001; 164(1): 44 - 47. [Full Text] [PDF]
|
|
|
|
|
|
J. E. R. van Lennep, H. T. Westerveld, H. W. O. R. van Lennep, A. H. Zwinderman, D. W. Erkelens, and E. E. van der Wall Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease Events Arterioscler Thromb Vasc Biol, November 1, 2000; 20(11): 2408 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Lemieux, A. Pascot, C. Couillard, B. Lamarche, A. Tchernof, N. Almeras, J. Bergeron, D. Gaudet, G. Tremblay, D. Prud'homme, et al. Hypertriglyceridemic Waist : A Marker of the Atherogenic Metabolic Triad (Hyperinsulinemia; Hyperapolipoprotein B; Small, Dense LDL) in Men? Circulation, July 11, 2000; 102(2): 179 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Vohl, P. Lepage, D. Gaudet, C. G. Brewer, C. Bétard, P. Perron, G. Houde, C. Cellier, J. M. Faith, J.-P. Després, et al. Molecular scanning of the human PPARa gene: association of the L162V mutation with hyperapobetalipoproteinemia J. Lipid Res., June 1, 2000; 41(6): 945 - 952. [Abstract] [Full Text]
|
|
|
|
|
|
G. F. Watts, F. M. Riches, S. E. Humphries, P. J. Talmud, and F. M. van Bockxmeer Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity J. Lipid Res., March 1, 2000; 41(3): 481 - 488. [Abstract] [Full Text]
|
|
|
|
|
|
G.F. WATTS, S. HERRMANN, and F.M. RICHES Effects of diet and serotonergic agonist on hepatic apolipoprotein B-100 secretion and endothelial function in obese men QJM, March 1, 2000; 93(3): 153 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Grundy, T. Bazzarre, J. Cleeman, R. B. D’Agostino Sr, M. Hill, N. Houston-Miller, W. B. Kannel, R. Krauss, H. M. Krumholz, R. M. Lauer, et al. Prevention Conference V : Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Medical Office Assessment : Writing Group I Circulation, January 4, 2000; 101 (1): e3 - e11. [Full Text] [PDF]
|
|
|
|
|
|
F. M. Riches, G. F. Watts, J. Hua, G. R. Stewart, R. P. Naoumova, and P. H. R. Barrett Reduction in Visceral Adipose Tissue Is Associated with Improvement in Apolipoprotein B-100 Metabolism in Obese Men J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2854 - 2861. [Abstract] [Full Text]
|
|
|
|
|
|
F. M. Riches, G. F. Watts, F. M. van Bockxmeer, J. Hua, S. Song, S. E. Humphries, and P. J. Talmud Apolipoprotein B signal peptide and apolipoprotein E genotypes as determinants of the hepatic secretion of VLDL apoB in obese men J. Lipid Res., September 1, 1998; 39(9): 1752 - 1758. [Abstract] [Full Text]
|
|
|
|
|
|
I. Jungner, S. M. Marcovina, G. Walldius, I. Holme, W. Kolar, and E. Steiner Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization–International Federation of Clinical Chemistry First International Reference Materials Clin. Chem., August 1, 1998; 44(8): 1641 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Sowers Obesity and cardiovascular disease Clin. Chem., August 1, 1998; 44(8): 1821 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. T. Westerveld, J. E. R. van Lennep, H. W. O. R. van Lennep, A.-H. Liem, J. A. J. de Boo, Y. T. van der Schouw, and D. W. Erkelens Apolipoprotein B and Coronary Artery Disease in Women : A Cross-sectional Study in Women Undergoing Their First Coronary Angiography Arterioscler Thromb Vasc Biol, July 1, 1998; 18(7): 1101 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lamarche, A. Tchernof, P. Mauriege, B. Cantin, G. R. Dagenais, P. J. Lupien, and J.-P. Despres Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size as Risk Factors for Ischemic Heart Disease JAMA, June 24, 1998; 279(24): 1955 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Bachorik, K. L. Lovejoy, M. D. Carroll, and C. L. Johnson Apolipoprotein B and AI distributions in the United States, 1988–1991: results of the National Health and Nutrition Examination Survey III (NHANES III) Clin. Chem., December 1, 1997; 43(12): 2364 - 2378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Perusse, T. Rice, J. P. Despres, D. C. Rao, and C. Bouchard Cross-Trait Familial Resemblance for Body Fat and Blood Lipids: Familial Correlations in the Quebec Family Study Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 3270 - 3277. [Abstract] [Full Text]
|
|
|
|
|
|
A. D. Sniderman Counterpoint To (measure apo)B or not to (measure apo)B: a critique of modern medical decision-making Clin. Chem., August 1, 1997; 43(8): 1310 - 1314. [Abstract] [Full Text]
|
|
|
|
|
|
B. Lamarche, A. Tchernof, S. Moorjani, B. Cantin, G. R. Dagenais, P. J. Lupien, and J.-P. Despres Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in Men: Prospective Results From the Quebec Cardiovascular Study Circulation, January 7, 1997; 95(1): 69 - 75. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Davidson, T. A. Lakka, H.-M. Lakka, J. T. Salonen, J.-P. Despres, B. Lamarche, and G. R. Dagenais Hyperinsulinemia and the Risk of Coronary Heart Disease N. Engl. J. Med., September 26, 1996; 335(13): 976 - 977. [Full Text]
|
|